An observational study in Pemphigus Vulgaris, sponsored by First Affiliated Hospital of Chongqing Medical University. Completed at 1 site in China. Open to participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-12.
Sponsored by First Affiliated Hospital of Chongqing Medical University · Observational
The objective of this retrospective study was to investigate the factors influencing in-hospital relapse during acute episodes of pemphigus, an autoimmune blistering disease characterized by self-antibodies targeting desmogleins. The study included 96 pemphigus patients hospitalized in China between January 2014 and December 2020. The primary questions addressed by the study were:
What are the risk factors associated with in-hospital relapse during acute episodes of pemphigus? Participants in the study underwent a retrospective analysis using univariate and multivariate Cox regression analysis to identify and understand the various risk factors contributing to in-hospital relapse. This research aimed to contribute valuable insights into the factors influencing the course of pemphigus, providing crucial information for better management and treatment strategies.
This retrospective study conducted in China between January 2014 and December 2020 aimed to comprehensively examine factors influencing in-hospital relapse during acute episodes of pemphigus, an autoimmune blistering disease characterized by self-antibodies targeting desmogleins-essential cell adhesion molecules. The study enrolled 96 pemphigus patients who were hospitalized during acute episodes.
Research Questions:
Primary Question:
What are the identifiable risk factors associated with in-hospital relapse in pemphigus patients during acute episodes?
Methods:
Study Type: Retrospective Observational Study Participant Population: 96 pemphigus patients hospitalized in China Duration: January 2014 to December 2020
Main Tasks:
Data Collection:
Retrospective analysis of medical records and clinical data of pemphigus patients during acute hospitalizations.
Identification of demographic information, clinical characteristics, and treatment modalities.
Risk Factor Determination:
Univariate and multivariate Cox regression analysis employed to assess potential risk factors.
Variables considered included demographic factors, disease severity, and specific treatment regimens.
Outcome Measurement:
Identification of in-hospital relapse as the primary outcome. Correlation of relapse occurrence with the identified risk factors.
Results:
Key Findings:
Identification of specific risk factors contributing to in-hospital relapse in pemphigus patients.
Quantification of the impact of demographic and clinical variables on relapse probability.
Significance:
Clinical Implications:
Contribution of valuable insights for clinicians in predicting and managing in-hospital relapse in pemphigus patients.
Informing treatment strategies based on identified risk factors.
Research Contribution:
Expansion of understanding regarding the course and management of pemphigus. Providing a foundation for future prospective studies and the development of targeted interventions.
76 studies on the registry are indexed under Pemphigus; 18 are open to participants now.
This study's enrollment of 96 is above the median of 60 across 21 observational studies indexed under Pemphigus.
Browse Pemphigus studies →First Affiliated Hospital of Chongqing Medical University is the lead sponsor of 95 studies on the registry; 42 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study included 96 patients diagnosed with pemphigus who received inpatient treatment at the First Affiliated Hospital of Chongqing Medical University between January 1st, 2014, and December 31st, 2020. The inclusion criteria covered both initial and follow-up cases, without age or sex restrictions. Diagnosis was confirmed through pathological biopsy, classifying pemphigus into different types. Patients underwent routine assessments, received various treatments, and were monitored for complications during hospitalization. Ten patients with multiple hospitalizations for cyclophosphamide pulse therapy and three patients not recovering were excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
in-hospitalization relapse
the occurrence of in-hospital relapse among pemphigus patients during acute episodes
Time frame: through hospitalization (Up to 1 month)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Jun 2022, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Chongqing Medical University